Stephen Feider Sells 1,427 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 1,427 shares of the company’s stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $29.34, for a total value of $41,868.18. Following the completion of the sale, the chief financial officer owned 42,614 shares in the company, valued at $1,250,294.76. This trade represents a 3.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Stephen Feider also recently made the following trade(s):

• On Friday, October 3rd, Stephen Feider sold 4,982 shares of Beta Bionics stock. The shares were sold at an average price of $21.69, for a total value of $108,059.58.
• On Wednesday, October 1st, Stephen Feider sold 15,018 shares of Beta Bionics stock. The stock was sold at an average price of $20.76, for a total transaction of $311,773.68.
• On Friday, September 5th, Stephen Feider sold 100 shares of Beta Bionics stock. The stock was sold at an average price of $21.00, for a total transaction of $2,100.00.

Beta Bionics Trading Down 1.3%

BBNX stock traded down $0.40 during trading on Thursday, hitting $30.00. 2,652,084 shares of the stock traded hands, compared to its average volume of 612,373. The stock has a market cap of $1.32 billion and a price-to-earnings ratio of -6.86. Beta Bionics, Inc. has a one year low of $8.89 and a one year high of $32.71. The company has a 50 day simple moving average of $24.99 and a 200 day simple moving average of $19.94.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings data on Tuesday, October 28th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.12. Beta Bionics had a negative net margin of 87.89% and a negative return on equity of 35.72%. The company had revenue of $27.25 million during the quarter, compared to analyst estimates of $23.92 million.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on BBNX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Beta Bionics in a research report on Monday. Lake Street Capital restated a “buy” rating and issued a $35.00 target price on shares of Beta Bionics in a research note on Wednesday, October 29th. Piper Sandler reiterated an “overweight” rating and set a $32.00 price target (up previously from $26.00) on shares of Beta Bionics in a research report on Wednesday, October 29th. Truist Financial reissued a “buy” rating and set a $32.00 price objective (up previously from $28.00) on shares of Beta Bionics in a report on Wednesday, October 29th. Finally, Wall Street Zen raised shares of Beta Bionics from a “strong sell” rating to a “hold” rating in a research note on Saturday, November 1st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $28.22.

Institutional Trading of Beta Bionics

A number of institutional investors and hedge funds have recently modified their holdings of BBNX. Jacobs Levy Equity Management Inc. acquired a new position in Beta Bionics in the 3rd quarter worth $775,000. Dark Forest Capital Management LP bought a new stake in shares of Beta Bionics in the third quarter valued at about $1,118,000. Verition Fund Management LLC lifted its holdings in shares of Beta Bionics by 4.0% in the third quarter. Verition Fund Management LLC now owns 47,299 shares of the company’s stock valued at $940,000 after purchasing an additional 1,823 shares in the last quarter. Vestal Point Capital LP boosted its position in shares of Beta Bionics by 9.1% during the third quarter. Vestal Point Capital LP now owns 600,000 shares of the company’s stock worth $11,922,000 after buying an additional 50,000 shares during the period. Finally, Mariner LLC bought a new position in shares of Beta Bionics during the third quarter worth about $425,000.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.